Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Jankovic

Showing results (321-330 of 574) with videos related to

Pageof 58
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|October 10, 2003
Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonismAmy N Hill, Joseph Jankovic, Kevin D A T Vuong, et al.
Journal of the Neurological Sciences|July 3, 2007
Distinguishing psychogenic and essential tremorChristopher Kenney, Alan Diamond, Nicte Mejia, et al.
Experimental Neurology|December 14, 2004
Age-dependent dopaminergic dysfunction in Nurr1 knockout miceChuantao Jiang, Xinhua Wan, Yi He, et al.
Journal of the Neurological Sciences|February 14, 2018
The nosology of tardive syndromesKaren Frei, Daniel D Truong, Stanley Fahn, et al.
Movement Disorders Clinical Practice|October 27, 2018
<i>SPG11</i> Mutations Associated With a Complex Phenotype Resembling Dopa-Responsive DystoniaSubhashie Wijemanne, Joshua M Shulman, Joohi Jimenez-Shahed, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 12, 2008
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assayMitchell F Brin, Cynthia L Comella, Joseph Jankovic, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2009
Impact of STN-DBS on life and health satisfaction in patients with Parkinson's diseaseJoseph Ferrara, Alan Diamond, Christine Hunter, et al.
Immunobiology|December 25, 2015
Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patientsMinako Oshima, Philip Deitiker, Joseph Jankovic, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 3, 2002
Olanzapine treatment for dopaminergic-induced hallucinationsWilliam G Ondo, Joel K Levy, Kevin Dat Vuong, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|July 3, 2015
Dopamine transporter imaging in essential tremor with and without parkinsonian featuresOlga Waln, Ying Wu, Reid Perlman, et al.
Pageof 58

Showing results (321-330 of 574) with videos related to

Sort By:
Pageof 58
Movement Disorders : Official Journal of the Movement Disorder Society|October 10, 2003
Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonismAmy N Hill, Joseph Jankovic, Kevin D A T Vuong, et al.
Journal of the Neurological Sciences|July 3, 2007
Distinguishing psychogenic and essential tremorChristopher Kenney, Alan Diamond, Nicte Mejia, et al.
Experimental Neurology|December 14, 2004
Age-dependent dopaminergic dysfunction in Nurr1 knockout miceChuantao Jiang, Xinhua Wan, Yi He, et al.
Journal of the Neurological Sciences|February 14, 2018
The nosology of tardive syndromesKaren Frei, Daniel D Truong, Stanley Fahn, et al.
Movement Disorders Clinical Practice|October 27, 2018
<i>SPG11</i> Mutations Associated With a Complex Phenotype Resembling Dopa-Responsive DystoniaSubhashie Wijemanne, Joshua M Shulman, Joohi Jimenez-Shahed, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 12, 2008
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assayMitchell F Brin, Cynthia L Comella, Joseph Jankovic, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2009
Impact of STN-DBS on life and health satisfaction in patients with Parkinson's diseaseJoseph Ferrara, Alan Diamond, Christine Hunter, et al.
Immunobiology|December 25, 2015
Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patientsMinako Oshima, Philip Deitiker, Joseph Jankovic, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 3, 2002
Olanzapine treatment for dopaminergic-induced hallucinationsWilliam G Ondo, Joel K Levy, Kevin Dat Vuong, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|July 3, 2015
Dopamine transporter imaging in essential tremor with and without parkinsonian featuresOlga Waln, Ying Wu, Reid Perlman, et al.
Pageof 58